Skip to main content

ORIGINAL RESEARCH article

Front. Aging
Sec. Aging and the Immune System
Volume 5 - 2024 | doi: 10.3389/fragi.2024.1479928
This article is part of the Research Topic Inflammatory Bowel Disease in the Elderly: Epidemiology, Pathophysiology, Clinical Aspects and Treatment Strategies View all articles

Global Burden of Inflammatory Bowel Disease in the Elderly: Trends from 1990 to 2021 and Projections to 2051

Provisionally accepted
Ying Liu Ying Liu 1Ju Li Ju Li 2Guangxia Yang Guangxia Yang 3Deqian Meng Deqian Meng 2Xianming Long Xianming Long 4Kai Wang Kai Wang 5*
  • 1 Department of Rheumatology and Immunology,The First People's Hospital of Yancheng,The Fourth Affiliated Hospital of Nantong University, Yancheng, China
  • 2 Department of Rheumatology and Immunology, The affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China
  • 3 Department of rheumatology, Affiliated Hospital of Jiangnan University, No.1000 Hefeng Road, WUXI, China
  • 4 Department of Rheumatology and Immunology, The First Affiliated Hospital of Soochow University, Soochow, China
  • 5 Department of Rheumatology, The affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China

The final, formatted version of the article will be published soon.

    Background: This study aims to analyze the historical trends of inflammatory bowel disease (IBD) burden in the elderly from 1990 to 2021 and forecast future trends up to 2051.Methods: Data from the Global Burden of Disease Study 2021 were utilized. Age-standardized rates (ASR) for incidence, prevalence, mortality, and disability-adjusted life years (DALYs) were calculated.Estimated annual percentage changes (EAPCs) were computed to quantify temporal trends. A Bayesian Age-Period-Cohort model was employed to project future trends.From 1990 to 2021, the global number of elderly IBD increased from 573,500 to 1,278,190.The age-standardized incidence rate (ASIR) rose from 8.01 to 8.77 per 100,000, while the age-standardized prevalence rate (ASPR) slightly decreased from 118.14 to 117.29 per 100,000. Death number increased from 14,400 to 33,490, but the age-standardized mortality rate decreased from 3.21 to 2.84 per 100,000. DALYs increased from 324,100 to 683,750, with the age-standardized DALYs rate declining from 68.78 to 60.88 per 100,000. Significant geographical variations were observed, with high Socio-demographic Index regions showing the highest burden. Projections suggest that by 2051, elderly IBD prevalence number may reach 2,316,000, with ASIR and ASPR potentially rising after 2035 and 2042, respectively. Deaths and DALYs are projected to increase to 75,000 and 1,401,000 respectively, despite continued declines in ASRs.The absolute burden of IBD in the elderly population is projected to increase substantially by 2051, despite decreasing ASRs. These findings underscore the need for tailored healthcare strategies and resource allocation to address the growing challenge of elderly IBD globally.

    Keywords: inflammatory bowel disease, Elderly, Global burden, Trends, projections

    Received: 13 Aug 2024; Accepted: 15 Oct 2024.

    Copyright: © 2024 Liu, Li, Yang, Meng, Long and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Kai Wang, Department of Rheumatology, The affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.